Page 289 - Vitamin D and Cancer

276 R. Okamoto et al.

121. Sokoloski JA, Sartorelli AC (Feb, 1998) Induction of the differentiation of HL-60 promyelocytic
leukemia cells by nonsteroidal anti-inflammatory agents in combination with low levels of
vitamin D3. Leuk Res 22(2):153–61
122. Bhatia M, Kirkland JB, Meckling-Gill KA (Oct, 1994) M-CSF and 1,25 dihydroxy vitamin
D3 synergize with 12-O-tetradecanoylphorbol-13-acetate to induce macrophage differentia-
tion in acute promyelocytic leukemia NB4 cells. Leukemia 8(10):1744–9
123. Danilenko M, Wang X, Studzinski GP (Aug 15, 2001) Carnosic acid and promotion of
monocytic differentiation of HL60-G cells initiated by other agents. J Natl Cancer Inst
93(16):1224–33
124. Danilenko M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski GP (Mar 15, 2003) Carnosic
acid potentiates the antioxidant and prodifferentiation effects of lalpha,25-dihydroxyvitamin
D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium.
Cancer Res 63(6):1325–32
125. Sharabani H, Izumchenko E, Wang Q, Kreinin R, Steiner M, Barvish Z, Kafka M, Sharoni
Y, Levy J, Uskokovic M, Studzinski GP, Danilenko M (June 15, 2006) Cooperative antitu-
mor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of
myeloid leukemia. Int J Cancer 118(12):3012–21
126. Wang X, Rao J, Studzinski GP (Aug 1, 2000) Inhibition of p38 MAP kinase activity up-
regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-
induced differentiation of human leukemia HL60 cells. Exp Cell Res 258(2):425–37
127. Wang Q, Harrison JS, Uskokovic M, Kutner A, Studzinski GP (Oct, 2005) Translational
study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination
with a p38 MAPK inhibitor and an antioxidant. Leukemia 19(10):1812–7
128. Torres R, Calle C, Aller P, Mata F (May, 2000) Etoposide stimulates 1,25-dihydroxyvitamin
D3 differentiation activity, hormone binding and hormone receptor expression in HL-60
human promyelocytic cells. Mol Cell Biochem 208(1–2):157–62
129. Siwińska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, Szelejewski W,
Radzikowski C (May–June 2001) Potentiation of the anti proliferative effect in vitro of doxoru-
bicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res 21(3B):1925–9
130. Ikezoe T, Bandobashi K, Yang Y, Takeuchi S, Sekiguchi N, Sakai S, Koeffler HP, Taguchi H
(Aug, 2006) HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvita-
min D3 to induce growth arrest and differentiation of human myeloid leukemia cells via
down-regulation of CYP24. Leuk Res 30(8):1005–11
131. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco
F, Nervi C, Pelicci PG, Heinzel T (Dec 17, 2001) Valproic acid defines a novel class of
HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969–78
132. Siitonen T, Timonen T, Juvonen E, Terävä V, Kutila A, Honkanen T, Mikkola M, Hallman
H, Kauppila M, Nyländen P, Poikonen E, Rauhala A, Sinisalo M, Suominen M, Savolainen
ER, Koistinen P, Pirjo Koistinen for the Finnish Leukemia Group (Aug, 2007) Valproic acid
combined with13-cis retinoic acid and 1,25 dihydroxyvitamin D3 in the treatment of patients
with myelodysplastic syndromes. Haematologica 92(8):1119–22
133. Mehta AB, Kumaran TO, Marsh GW, McCarthy DM (Sep 29, 1984) Treatment of advanced
myelodysplastic syndrome with alfacalcidol. Lancet 2(8405):761
134. Motomura S, Kanamori H, Maruta A, Kodama F, Ohkubo T (Sep, 1991) The effect of
1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelo-
dysplastic syndromes. Am J Hematol 38(1):67–8
135. Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ,
Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB,
Kyllo DM, Douglass LL, Bishop CW, Coburn JW (Sep, 2000) Intermittent doxercalciferol
(lalpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis
36(3):550–61
136. Mellibovsky L, Díez A, Aubia J, Nogues X, Pérez-Vila E, Serrano S, Recker RR (Dec, 1993)
Long-standing remission after 25–0H D3 treatment in a case of chronic myelomonocytic
leukaemia. Br J Haematol 85(4):811–2